Payment overview · 2025
General Payments
$2,269.54
111 reported records · 26 companies
Healthcare provider profile · identity verified
Mark E Skees, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORFOLK, VA · NPI 1861571499
Verified facts
What the public records show
CMS Open Payments records show Mark E Skees, MD received $2,269.54 in general payments during 2025 across 111 reported records.
PFIZER INC. accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $372.32 | 16.4% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $370.84 | 16.3% | 24 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $229.35 | 10.1% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $207.93 | 9.2% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $144.01 | 6.3% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $107.87 | 4.8% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $79.69 | 3.5% | 4 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $71.77 | 3.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $70.67 | 3.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $69.06 | 3.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $62.54 | 2.8% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $57.02 | 2.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.11 | 2.4% | 3 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $53.49 | 2.4% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $52.49 | 2.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $46.21 | 2.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$31.34 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.47 | 1.2% | 2 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $27.81 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.98 | 1.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $21.50 | 0.9% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $21.42 | 0.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.58 | 0.8% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $17.01 | 0.8% | 1 | 2025 |
| Endo USA, Inc. | Unresolved — no canonical attribution shown | $15.06 | 0.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.00 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,269.54 | 111 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $319.39 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $238.27 | 15 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $192.31 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $187.90 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $185.71 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $181.85 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $168.61 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $132.57 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $128.64 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $128.64 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $107.87 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $93.59 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $79.69 | 4 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $71.77 | 2 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $71.77 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $70.99 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $70.67 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $62.54 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $57.02 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.40 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.11 | 3 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $53.49 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $52.93 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $52.93 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $52.93 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $52.49 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.98 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $46.21 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $46.00 | 3 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $31.34 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| AVEED Normalized: aveed |
Biological | Endo USA, Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| XIAFLEX Normalized: xiaflex |
Biological | Endo USA, Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $10.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 86 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 609 | 173 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 417 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 256 | 82 |
| Losartan Potassium | Losartan Potassium | 244 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 51 |
| Trazodone Hcl | Trazodone Hcl | 168 | 45 |
| Meloxicam | Meloxicam | 164 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 49 |
| Metformin Hcl | Metformin Hcl | 147 | 46 |
| Omeprazole | Omeprazole | 141 | 36 |
| Lisinopril | Lisinopril | 135 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 35 |
| Gabapentin | Gabapentin | 109 | 30 |
| Allopurinol | Allopurinol | 96 | 28 |
| Alprazolam | Alprazolam | 92 | 21 |
| Eliquis | Apixaban | 86 | 22 |
| Bupropion Xl | Bupropion Hcl | 81 | 22 |
| Furosemide | Furosemide | 76 | 25 |
| Montelukast Sodium | Montelukast Sodium | 76 | 22 |
| Prednisone | Prednisone | 76 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 34 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 74 | 12 |
| Ezetimibe | Ezetimibe | 72 | 26 |
| Tramadol Hcl | Tramadol Hcl | 69 | 16 |
| Farxiga | Dapagliflozin Propanediol | 68 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 47 |
| Carvedilol | Carvedilol | 64 | 17 |
| Sertraline Hcl | Sertraline Hcl | 62 | 20 |
| Glimepiride | Glimepiride | 61 | 18 |
| Ozempic | Semaglutide | 61 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | 11 |
| Lorazepam | Lorazepam | 52 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 13 |
| Metformin Hcl Er | Metformin Hcl | 47 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 18 |
| Jardiance | Empagliflozin | 45 | suppressed |
| Simvastatin | Simvastatin | 45 | 12 |
| Potassium Chloride | Potassium Chloride | 44 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 13 |
| Valacyclovir | Valacyclovir Hcl | 43 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 26 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Finasteride | Finasteride | 38 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 16 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 11 |
| Fluconazole | Fluconazole | 28 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Nystatin | Nystatin | 28 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Clarithromycin | Clarithromycin | 13 | 13 |
| Naproxen | Naproxen | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Zolmitriptan | Zolmitriptan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,269.54 · 111 records | PFIZER INC. | ABRYSVO, ACCRUFER, AIRSUPRA, APLENZIN, AREXVY, AVEED, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CRYSVITA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, INTELLIS ADAPTIVESTIM, KISUNLA, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, OFEV, OPSUMIT, Ozempic, PRECIVITYAD2, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, SPRAVATO, Symbravo, TMS NeuroHealth Centers Inc., TRELEGY ELLIPTA, UBRELVY, UPTRAVI, VRAYLAR, VYEPTI, Veozah, WELLBUTRIN, Wegovy, XIAFLEX, YUPELRI, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error